• PDF: Delivered by email usually within 48 UK business hours.

Rigel Pharmaceuticals, Inc. (RIGL) - Pharmaceuticals & Healthcare
Deals and Alliances Profile

  • Publication Date:March 2011
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:104

Rigel Pharmaceuticals, Inc. (RIGL) - Pharmaceuticals & Healthcare Deals and Alliances Profile

Rigel Pharmaceuticals, Inc. (RIGL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Rigel Pharmaceuticals, Inc. (Rigel) is a clinical-stage drug development company. The company is engaged in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Rigel develops its products based on signaling pathways and related targets that are critical to disease mechanisms. The company is headquartered at South San Francisco in California, the US.

Its current research programs include Inhibition of JAK3 kinase for immune disorders and Inhibition of PKC theta for MS and IBD. The company has partnered programs in asthma and oncology.

Rigel Pharmaceuticals, Inc. (RIGL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you an in-depth data and trend analysis of the company's mergers and acquisitions (M&A) and financings. The report provides detailed information on M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions registered by the company over a five year period. The report portrays detailed comparative data on the number of deals and their value subdivided by deal types, markets, and regions, besides highlighting the company's major recent financial deals.

Data presented in this report was derived from GlobalData's proprietary in-house Pharmaceuticals and Healthcare eTrack deals database and primary and secondary research.

Scope

  • Financial Deals - Analysis of the company's financial deals including M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information on the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information on the number of deals and value reported by the company by type such as M&A, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region for North America, Europe, the Middle East and Africa and South and Central America.
  • Deals by Market - Chart and table showing information on the number of deals and value reported by the company, by market.
  • Major Recent Deals - Information on the company's major recent financial deals. Each such deal has a brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key Competitors - A list of key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements.

  • The profile analyzes the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divesture strategy

  • Deals are presented from the company's core business segments' perspective to help you understand its corporate strategy

Access detailed information about the company's recent financial deals that enables you to understand the key deals which have shaped the company

  • Major recent deals are presented in detail, which provides information on each deal's brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company to identify potential customers and suppliers.

  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and their biographies and key competitors.

Stay up to date on the major developments affecting the company

  • Recent developments in the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research.

  • Key elements such as break up of deals by categories and information on detailed major deals are incorporated in the profile to assist your academic or business research needs.

This report covers the following industry codes:
SIC Code: 8731
NAICS Code: 54171

  • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
    • Merck Serono Expands Licenisng Agreement With Rigel Pharmaceuticals
    • Partnerships
    • Rigel Pharmaceuticals Announces Co-Development Agreement For R348
    • Proteros Biostructures Extends Research Agreement With Rigel Pharmaceuticals
    • Graffinity Pharmaceuticals Enters Into Co-Development Agreement With Rigel Pharmaceuticals
    • Licensing Agreements
    • AstraZeneca Enters Into Licensing Agreement With Rigel Pharmaceuticals
    • Rigel Pharmaceuticals Enters Into Licensing Agreement With Merck Serono
    • Rigel Pharmaceuticals Signs An Agreement With Pfizer
    • Equity Offering
    • Rigel Pharmaceuticals Completes Public Offering Of Its Common Stock For $108 Million
    • Rigel Pharmaceuticals Completed the Public Offering of $135 Million
    • Rigel Pharmaceuticals Completes Public Offering Of $56.06 Million
    • Rigel Pharmaceuticals Completes Private Placement Of $15 Million
    • Rigel Pharmaceuticals Completes Public Offering Of $87 Million
    • Rigel Pharmaceuticals Completes Private Placement Of $5 Million
    • Key Competitors
    • Key Employees
    • Locations And Subsidiaries
    • Head Office
    • Recent Developments
    • Financial Announcements
    • Mar 01, 2011: Rigel Reports Net Loss Of $17.2m For Q4 2010
    • Nov 02, 2010: Rigel Reports Net Income Of $50.4 Million For Q3 2010
    • Aug 03, 2010: Rigel Reports Net Income Of $27 Million For Q2 2010
    • May 04, 2010: Rigel Reports Net Loss Of $22.3 Million For Q1 2010
    • Mar 02, 2010: Rigel Reports Net Loss Of $25.1 Million For Q4 2009
    • Nov 03, 2009: Rigel Q3 2009 Net Loss Narrows
    • Aug 04, 2009: Rigel Reports Net Loss Of $29.8 Million For Q2 2009
    • May 05, 2009: Rigel Q1 2009 Net Loss Increases
    • Feb 24, 2009: Rigel Reports Net Loss Of $33.4 Million For Q4 2008
    • Nov 03, 2008: Rigel Announces Third Quarter 2008 Financial Results And Clinical Update
    • Aug 05, 2008: Rigel Announces Second Quarter 2008 Financial Results
    • May 06, 2008: Rigel Announces First Quarter 2008 Financial Results
    • Feb 12, 2008: Rigel Announces Fourth Quarter And Year End 2007 Financial Results
    • Nov 06, 2007: Rigel Announces Third Quarter 2007 Financial Results
    • Aug 07, 2007: Rigel Announces Second Quarter 2007 Financial Results
    • May 10, 2007: Rigel Announces First Quarter 2007 Financial Results
    • Feb 06, 2007: Rigel Announces Fourth Quarter And Year End 2006 Financial Results
    • Nov 07, 2006: Rigel Announces Third Quarter 2006 Financial Results
    • Aug 02, 2006: Rigel Announces Second Quarter 2006 Financial Results
    • May 02, 2006: Rigel Announces First Quarter 2006 Financial Results
    • Feb 07, 2006: Rigel Announces Fourth Quarter And Year End 2005 Financial Results
    • Nov 08, 2005: Rigel Announces Third Quarter 2005 Financial Results
    • Aug 03, 2005: Rigel Announces Second Quarter 2005 Financial Results
    • May 03, 2005: Rigel Announces First Quarter 2005 Financial Results
    • Feb 08, 2005: Rigel Announces Fourth Quarter And Year End 2004 Financial Results
    • Nov 05, 2004: Rigel Announces Third Quarter 2004 Financial Results
    • Aug 03, 2004: Rigel Announces Second Quarter 2004 Financial Results
    • May 04, 2004: Rigel Announces First Quarter 2004 Financial Results
    • Feb 03, 2004: Rigel Announces Fourth Quarter And Year End 2003 Financial Results
    • Nov 05, 2003: Rigel Announces Third Quarter 2003 Financial Results
    • Aug 05, 2003: Rigel Announces Second Quarter 2003 Financial Results
    • May 06, 2003: Rigel Announces First Quarter 2003 Financial Results
    • Feb 05, 2003: Rigel Announces 2002 Fiscal Year Financial Results
    • Nov 04, 2002: Rigel Announces Third Quarter Financial Results
    • Aug 06, 2002: Rigel Announces Second Quarter 2002 Financial Results
    • May 07, 2002: Rigel Announces First Quarter 2002 Financial Results
    • Feb 05, 2002: Rigel Announces Fourth Quarter And Year End 2001 Financial Results
    • Nov 07, 2001: Rigel Reports Third Quarter 2001 Financial Results
    • Aug 08, 2001: Rigel Reports Second Quarter 2001 Financial Results
    • May 08, 2001: Rigel Reports First Quarter 2001 Financial Results
    • Feb 07, 2001: Rigel Reports Fourth Quarter And Year 2000 Financial Results
    • Research And Development
    • Jun 01, 2009: Rigel' R788 Evaluated In Phase II Trial In Multiple Cancers
    • Corporate Communications
    • Jun 01, 2010: Rigel Names Raul Rodriguez As President
    • Mar 21, 2006: Rigel Granted Key Patents In Immunology, Virology And Oncology
    • Apr 02, 2002: Rigel Pharmaceuticals Appoints Elliott Grossbard, M.D., Senior Vice President Of Medical Development
    • Product News
    • Dec 21, 2004: Rigel Initiates Clinical Trial In Rheumatoid Arthritis
    • Dec 11, 2003: Rigels R112 For Allergic Rhinitis Achieves Positive Safety Profile
    • Dec 07, 2008: Phase 2 Results Of Rigels R788 Show Clinical Benefit In Diffuse Large B-Cell Lymphoma And Cll
    • Dec 04, 2000: Rigel Receives U.S. Patent For Unique Method Of Genomic Screening
    • Dec 03, 2008: Rigel To Host Conference Call To Discuss Phase 2 Study Results Of R788 In Lymphoma Presented At Ash
    • Dec 01, 2009: Eleven Rigel Product Candidate Presentations At 2009 Ash Meeting
    • Dec 01, 2005: Rigel Announces Disappointing Results From Phase Ii Study Of R112 For The Treatment Of Allergic Rhinitis
    • Nov 22, 2004: Poor Bioavailability Results In Insignificant Clinical Effects For Rigel R803 In Phase I/Ii Hcv Trial Next Steps For Clinical Program To Be Outlined At Analyst Day, December 1st
    • Nov 14, 2005: Rigel Announces Presentation Of Phase I Data On R406/788 At The American College Of Rheumatology (Acr) Annual Meeting
    • Nov 12, 2003: Rigel Initiates Clinical Trial In Hepatitis C
    • Nov 11, 2008: Rigels R788 Phase 2a Results Published In Arthritis And Rheumatism
    • Oct 21, 2008: Rigel To Webcast Investor Update On October 27, 2008
    • Oct 16, 2009: Rigel To Webcast Analyst Briefing On October 20, 2009
    • Oct 11, 2001: Rigel Disusses Two Lead Product Canidates At Ubs Warburg Conference
    • Oct 07, 2002: Rigel Reports Progress On Drug Development Programs
    • Sep 25, 2000: Rigel Receives Patent For Mammalian Two-Hyrid Technology
    • Sep 18, 2002: Rigel Moves First Drug Into Clinical Testing
    • Sep 10, 2003: Rigel Initiates Multi-Dose Safety Trial Of R112 For Allergic Rhinitis
    • Sep 06, 2006: Rigel Announces Initiation Of Phase Ii Study Evaluating R788 In Rheumatoid Arthritis
    • Aug 09, 2005: Rigel Initiates Comparative Phase Ii Clinical Trial Of R112 For The Treatment Of Allergies
    • Aug 02, 2004: Rigels R112 Demonstrates Robust Effect In Reducing Symptoms Of Allergic Rhinitis In Large Phase Ii Clinical Trial
    • Jul 23, 2009: R788 In Taski3 Clinical Trial Does Not Meet Efficacy Endpoints In Ra Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
    • Jul 22, 2004: Rigel Reports Significant Progress In Aurora Kinase Program For The Treatment Of Cancer
    • Jul 20, 2003: Rigel Completes Clinical Trial Of R112 In Allergic Rhinitis
    • Jul 09, 2009: Rigel Reports Positive Results For Phase 2b RA Trial
    • Jul 09, 2009: Rigels R788 Significantly Improves Rheumatoid Arthritis In Phase 2b Clinical Trial
    • Jul 08, 2009: Rigel To Host Conference Call To Discuss Results Of Its Phase 2b Taski2 Clinical Trial Of R788 In Rheumatoid Arthritis
    • Jul 06, 2005: Rigel's Productivity On Track: Hcv And R&D Pipeline Update
    • Jun 24, 2002: Rigel And Inoxell Enter Global Patent Settlement Agreement
    • Jun 09, 2004: Rigel Granted Key Patents In Ubiquitin Ligase Field
    • Jun 01, 2009: Rigel' R788 Evaluated In Phase II Trial In Multiple Cancers
    • Jun 01, 2009: Rigels R788 Evaluated In Phase 2 Trial In Multiple Cancers
    • May 31, 2001: Rigel Accelerates Asthma/Allergy Program Through Agreement With Albany Molecular Research
    • May 24, 2004: Rigel Initiates Phase I/Ii Trial Of R803 For The Treatment Of Hepatitis C Virus
    • May 22, 2002: Rigel Announces Novartis Acceptance Of Drug Target And Conclusion Of Research Phase Of Two Programs
    • May 06, 2002: Rigel Delivers Additional Respiratory Drug Research Targets And Completes Discovery Phase Of Target Identification Collaboration With Pfizer
    • Apr 29, 2008: Rigel's R788 Slows Progression Of Murine Lupus In Preclinical Studies
    • Apr 20, 2004: Rigel Initiates Phase Ii Clinical Trial Of R112 For Allergic Rhinitis
    • Apr 06, 2005: Efficacy And Safety Clinical Data For Rigels R112 Phase Ii Study Published In Journal Of Allergy And Clinical Immunology
    • Mar 31, 2005: Rigel Completes Phase I Clinical Trial Of R406 In Rheumatoid Arthritis
    • Mar 29, 2001: Rigel Receives U.S. Patent For Unique Use Of Green Fluorescent Protein In Genomic Screening
    • Mar 18, 2004: Rigel Presents Positive Results Of R112 Clinical Trial For Treatment Of Allergic Rhinitis
    • Mar 13, 2009: Rigel Commences Phase 2 Trial Of R788 In Peripheral T-Cell Lymphomas
    • Mar 05, 2003: Rigel Pharmaceuticals Presents Drug Development Programs In Oncology And Allergy/Inflammation At The Protein Phosphorylation Drug Discovery World Summit
    • Feb 16, 2010: Astrazeneca And Rigel Pharmaceuticals Sign Worldwide License Agreement For Late-Stage Development Product -- Fostamatinib Disodium (R788) -- For The Treatment Of Rheumatoid Arthritis (Ra)
    • Feb 03, 2009: Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
    • Jan 30, 2001: Rigel Names Gregory S. Wagner, Ph.D. To Head Preclinical Development Activities
    • Jan 26, 2004: Rigels R803 For Hcv Achieves Favorable Safety Profile
    • Jan 13, 2003: Rigel Begins U.S. Clinical Testing Of Allergy Drug
    • Jan 09, 2008: Rigel Announces Initiation Of Phase 1 Clinical Trial Of R348 For Rheumatoid Arthritis, Psoriasis And Other Immune Disorders
    • Jan 06, 2004: Rigel Announces Issuance Of Hcv And Inflammation Patents
  • Appendix
    • Methodology
    • About GlobalData
    • Contact Us
    • Disclaimer 104
  • List of Tables
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Key Facts, 2009
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Deals By Therapy Area, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Merck Serono Expands Licenisng Agreement With Rigel Pharmaceuticals
    • Rigel Pharmaceuticals Announces Co-Development Agreement For R348
    • Proteros Biostructures Extends Research Agreement With Rigel Pharmaceuticals
    • Graffinity Pharmaceuticals Enters Into Co-Development Agreement With Rigel Pharmaceuticals
    • AstraZeneca Enters Into Licensing Agreement With Rigel Pharmaceuticals
    • Rigel Pharmaceuticals Enters Into Licensing Agreement With Merck Serono
    • Rigel Pharmaceuticals Signs An Agreement With Pfizer
    • Rigel Pharmaceuticals Completes Public Offering Of Its Common Stock For $108 Million
    • Rigel Pharmaceuticals Completed the Public Offering of $135 Million
    • Rigel Pharmaceuticals Completes Public Offering Of $56.06 Million
    • Rigel Pharmaceuticals Completes Private Placement Of $15 Million
    • Rigel Pharmaceuticals Completes Public Offering Of $87 Million
    • Rigel Pharmaceuticals Completes Private Placement Of $5 Million
    • Rigel Pharmaceuticals, Inc., Key Employees 38
  • List of Figures
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals by Year, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals by Phase, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Rigel Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
+44 20 8816 8548

Ask a question about Rigel Pharmaceuticals, Inc. (RIGL) - Pharmaceuticals & Healthcare

Enter the characters you see in the picture below
Captcha